NasdaqGS:ANABBiotechs
AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus
AnaptysBio has approved the spin off of First Tracks Biotherapeutics, with shareholders set to receive one First Tracks share for each AnaptysBio share held.
First Tracks Biotherapeutics is expected to list on Nasdaq and will be funded through capital from AnaptysBio and a private placement.
The company has added experienced industry executive Susannah Gray to its board as part of the transition.
The spin off comes as AnaptysBio, listed as NasdaqGS:ANAB, is in focus with a current share...